Trials / Unknown
UnknownNCT05706324
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
A Single-arm, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation in People 21 to 65 Years Old (Previously Primed With Authorized Vaccines)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Wuhan BravoVax Co., Ltd. · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi) at low, medium, and high doses in healthy adults (previously primed with authorized vaccines).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation | 0.2mL/dose, Inhalation using a nebulizer |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2023-12-01
- Completion
- 2024-07-01
- First posted
- 2023-01-31
- Last updated
- 2023-04-25
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05706324. Inclusion in this directory is not an endorsement.